1. Pink Sheet

Global Summit Hears Pledges To Cut Pandemic Vaccine Development Times

Cooperation Is Key To Tackling Health Threats

 
• By Ian Schofield

Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.

Business team connect pieces of gears. Teamwork, partnership and integration concept
Global cooperation is the key to tackling future health emergencies • Source: Alamy

Biotech and vaccine manufacturers, the Coalition for Epidemic Preparedness Innovations (CEPI) and the UK government have outlined the steps they plan to take to achieve the “100-Days Mission” – a pledge to reduce the time taken to develop new vaccines within 100 days of the identification of a new pathogen with epidemic or pandemic potential.

“Today, industry has stepped forward to commit its expertise and resources to achieving the 100 Days Mission, including by investing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 
• By Francesca Bruce

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines 30th anniversary.

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 
• By Bridget Silverman

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.